GENITOURINARY CANCERS

Neeraj Agarwal, MD, recently discussed the treatment considerations and decisions he makes when treating patients with renal cell carcinoma. Agarwal, director of the Genitourinary Oncology Program, University of Utah School of Medicine, explained his treatment decisions based on a case scenario during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.

Based on data from the phase III CheckMate-214 trial, the&nbsp;combination of&nbsp;nivolumab (Opdivo) and ipilimumab (Yervoy) has been approved by the FDA&nbsp;as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma.

According to findings from the phase III ATLAS trial, disease-free survival was not extended with adjuvant axitinib (Inlyta) versus placebo for patients at high risk of&nbsp;recurrent renal cell carcinoma after nephrectomy.

Several new indications were approved by the FDA in March, including blinatumomab (Blincyto)&nbsp;for MRD+ ALL, brentuximab vedotin (Adcetris) for Hodgkin lymphoma, and a 4-week nivolumab (Opdivo) dosing schedule across several indications. Here&rsquo;s a look back on the FDA happenings for the month of March 2018.

Prostate Cancer

Based on data from the phase III PROSPER trial, a supplemental new drug application for enzalutamide for the treatment of men with nonmetastatic castration-resistant prostate cancer has been granted a priority review by the FDA,&nbsp;according to Pfizer and Astellas, the companies developing the antiandrogen agent.

Lung Cancer

Based on the phase II study BLC2001, erdafitinib has been granted a breakthrough therapy designation by the FDA for the treatment of&nbsp;metastatic urothelial carcinoma,&nbsp;according to Janssen, the manufacturer of the oral pan-FGFR tyrosine kinase inhibitor.

<em>Targeted Therapies in Oncology</em>, an oncology resource that provides oncology professionals with cutting-edge research, data, and treatment strategies surrounding molecular and immune system targets, welcomes&nbsp;Arjun V. Balar, MD,&nbsp;as its editor-in-chief.

Bridget F. Koontz, MD, associate professor of radiation oncology, Duke Cancer Institute, discusses a single-arm, phase II trial of 6 months of concurrent androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

A supplemental new drug application for Blue Light Cytoscopy with Cysview, a procedure for detecting bladder cancer, was recently approved by the FDA.